Management of patients with actinic keratoses

Hepplewhite, Alison

doi:10.12968/bjon.2012.21.sup7.s27

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 The efficacy can be increased by the use of 3% diclofenac gel or 5-FU as pretreatment as reported by some data in the literature. 33,34 Imiquimod 5% post cryotherapy may increase removal and destruction of target, subclinical, and total AKs. 24,35 Laser therapy Laser therapy is probably one of the most effective techniques, even if it is more expensive and characterized by a higher learning curve compared to cryotherapy.…”

Section: Cryotherapymentioning

confidence: 99%

Current therapies for actinic keratosis

et al. 2020

View full text Add to dashboard Cite

Actinic keratosis (AK) is a very common skin disease caused by chronic sun damage, which in 75% of cases arises on chronically sun-exposed areas, such as face, scalp, neck, hands, and forearms. AKs must be considered an early squamous cell carcinoma (SCC)for their probable progression into invasive SCC. For this reason, all AK should be treated, and clinical follow-up is recommended. The aims of treatment are: (i) to clinically eradicate evident and subclinical lesions, (ii) to prevent their evolution into SCC, and (iii) to reduce the number of relapses. Among available treatments, it is possible to distinguish lesiondirected therapies and field-directed therapies. Lesion-directed treatments include: (i) cryotherapy; (ii) laser therapy; (iii) surgery; and (iv) curettage. Whereas, field-directed treatments are: (i) 5-fluorouracil (5-FU); (ii) diclofenac 3% gel; (iii) chemical peeling; (iv) imiquimod; and (v) photodynamic therapy (PDT). Prevention plays an important role in the treatment of AKs, and it is based on the continuous use of sunscreen and protective clothing. This review shows different types of available treatments and describes the characteristics and benefits of each medication, underlining the best choice.

show abstract

Section: Cryotherapymentioning

confidence: 99%

Current therapies for actinic keratosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This probably reflects the fact that a course of IngMeb treatment, which lasts 2 or 3 days, is completed faster than that of other topical agents, which require daily applications for several weeks or months. Because patients may have had multiple areas that required treatment [1][2][3][4][5], the shorter dosing duration allowed physicians to treat other areas sooner, potentially producing faster resolution of all lesions.…”

Section: Discussionmentioning

confidence: 99%

“…Actinic keratoses (AK) are keratotic cutaneous lesions that may progress to invasive squamous cell carcinoma (SCC). AK lesions commonly occur in sun-exposed skin, such as on the head, neck, hands, and lower legs [1][2][3]. Risk factors for AK include fair skin, older age, baldness, immunodeficiency, and high cumulative ultraviolet radiation exposure [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

Asche

Zografos²,

Norlin³

et al. 2016

Value in Health

View full text Add to dashboard Cite

Results based on the first 6 months after treatment initiation suggested that most field-directed AK therapies had clinically comparable treatment patterns except imiquimod, which was associated with higher refill rates, and PDT, which was associated with significantly more frequent treatment sessions and higher switching rates. IngMeb was also associated with significantly fewer outpatient visits than were other field-directed therapies.

show abstract

Management of patients with actinic keratoses

Cited by 2 publications

References 0 publications

Current therapies for actinic keratosis

Current therapies for actinic keratosis

Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States

Contact Info

Product

Resources

About